Literature DB >> 9067095

Upmodulation of multinucleated cell formation in long-term human bone marrow cultures by leukaemia inhibitory factor (LIF).

D Heymann1, F Gouin, J Guicheux, J C Munevar, A Godard, G Daculsi.   

Abstract

Inflammatory processes are mediated by many cellular events involving different cell types (leukocytes, monocytes, stromal cells, etc.). Numerous soluble mediators regulate these reactions, including leukaemia inhibitory factor (LIF), a cytokine which may play an important role in inducing acute-phase protein synthesis by hepatocytes during inflammation. This study was designed to determine the effects of LIF on the human monocyte/macrophage lineage and provide a better definition of its behaviour during systemic inflammation. In-vitro exposure of human long-term bone marrow cultures to recombinant human LIF significantly increased (about two-fold) the number of multinucleated cells (MNC) formed after three weeks of culture. These LIF-induced MNC expressed tartrate-resistant acid phosphatase, and LIF increased this intracellular activity by about 50%. MNC displayed phagocytotic activity but were unable to degrade sperm whale dentin or respond to human calcitonin. They did not possess the main characteristics of osteoclasts and were in fact macrophage polykaryons. Our results demonstrate for the first time that LIF can induce macrophage polykaryon formation from human bone marrow culture, suggesting that this factor not only produces leukocytes but also has a direct influence on the monocyte/macrophage lineage.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9067095     DOI: 10.1006/cyto.1996.0134

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  1 in total

1.  A simplified method for the generation of human osteoclasts in vitro.

Authors:  James J Cody; Angel A Rivera; Jianzhong Liu; Julian M Liu; Joanne T Douglas; Xu Feng
Journal:  Int J Biochem Mol Biol       Date:  2011-04-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.